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Abstract
Background: Rapid molecular diagnostics for detecting multidrug-resistant and extensively drug-resistant tuberculosis (M/
XDR-TB) primarily identify mutations in Mycobacterium tuberculosis (Mtb) genes associated with drug resistance. Their
accuracy, however, is dependent largely on the strength of the association between a specific mutation and the phenotypic
resistance of the isolate with that mutation, which is not always 100%. While this relationship is well established and reliable
for first-line anti-TB drugs, rifampin and isoniazid, it is less well-studied and understood for second-line, injectable drugs,
amikacin (AMK), kanamycin (KAN) and capreomycin (CAP).
Methodology/Principal Findings: We conducted a systematic review of all published studies evaluating Mtb mutations
associated with resistance to AMK, KAN, CAP in order to characterize the diversity and frequency of mutations as well as
describe the strength of the association between specific mutations and phenotypic resistance in global populations. Our
objective was to determine the potential utility and reliability of these mutations as diagnostic markers for detecting AMK,
KAN and CAP resistance. Mutation data was reviewed for 1,585 unique clinical isolates from four continents and over 18
countries. Mutations in the rrs, tlyA, eis promoter and gidB genes were associated with AMK, KAN and/or CAP resistance.
Conclusions/Significance: The rrs A1401G mutation was present in the majority of AMK, KAN and CAP resistant Mtb strains
reviewed, but was also found in 7% of CAP susceptible strains. The 1401 mutation alone, however, was not found with
sufficient frequency to detect more than 70–80% of global Mtb strains resistant to AMK and CAP, and 60% of strains
resistant to KAN. Additional mutations in the rrs, eis promoter, tlyA and gidB genes appear to be associated with resistance
and could improve sensitivity and specificity of future diagnostics.
Citation: Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, et al. (2012) Evaluation of Genetic Mutations Associated with Mycobacterium
tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A Systematic Review. PLoS ONE 7(3): e33275. doi:10.1371/journal.pone.0033275
Editor: Laura Ellen Via, National Institute of Allergy and Infectious Disease, United States of America
Received December 16, 2011; Accepted February 12, 2012; Published March 29, 2012
Copyright:  2012 Georghiou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIAID grants #K01AI083784 to Dr. Timothy Rodwell and #U01AI082229 to Dr. Antonio Catanzaro, Dr. Marisa Magana, Dr.
Richard Garfein, and Dr. Donald Catanzaro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: trodwell@ucsd.edu
Introduction
In 2010, 8.8 million new cases of tuberculosis (TB) and 1.4
million TB-related deaths were reported worldwide [1]. While the
global incidence of TB appears to be decreasing, the emergence of
multidrug-resistant TB (MDR-TB) and extensively drug-resistant
TB (XDR-TB) has significantly complicated TB eradication
efforts. MDR-TB strains, as defined by World Health Organiza-
tion (WHO), are Mycobacterium tuberculosis (Mtb) strains resistant to
the most effective ‘‘first-line’’ TB medications: isoniazid (INH) and
rifampin (RIF). XDR-TB strains are characterized by resistance to
INH, RIF (ie MDR-TB) plus any fluoroquinolone (e.g., moxi-
floxacin), and at least one of the three ‘‘injectable’’ anti-TB drugs:
amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) [2].
At an estimated 5% of all tuberculosis cases globally, the incidence
of MDR-TB recently reported by the WHO is the highest ever
recorded [3], and XDR-TB cases have been confirmed in 58
countries to date [4].
Appropriate use of the ‘‘second-line’’ injectable drugs, AMK,
KAN and/or CAP is critical to the effective treatment of MDR-
TB and to the prevention of XDR-TB. It is therefore imperative
that the MDR-TB strains in patients starting second-line drug
treatment are first tested for sensitivity to these drugs to ensure
appropriate treatment choices are made and that resistance is not
further amplified [5]. Conventional diagnosis of drug-resistance in
Mtb strains relies heavily upon mycobacterial culture and drug
susceptibility testing in liquid or solid media. While this method is
effective for detecting INH and RIF resistance, detecting resistance
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Additionally, results are only obtained after weeks to months of
incubation and many developing countries lack the resources to
establish the stringent laboratory conditions needed for these
growth-based methods. From a clinical perspective, the existing
growth-based diagnostics also reveal too little, too late, as patients
undergoing treatment with drugs to which they are resistant,
remain contagious, and those with XDR-TB and HIV often die
before they are even diagnosed [7]. Rapid molecular diagnostic
tests that do not rely upon the culture of this slow-growing
pathogen are essential to the future management of M/XDR-TB.
Molecular diagnostics, which focus on the detection of mutations
in pathogen genes that have been associated with drug resistance,
have shown the most promise for rapid diagnosis of M/XDR-TB
[8–10]. Their accuracy, however, is dependent largely on the
strengthoftheassociationbetweenaspecificMtbgenemutationand
the phenotypic resistance of the isolate with that mutation, which is
not always 100%. This relationship between mutation and
phenotypic resistance is well established and consistent for the
first-line drug RIF [11,12], and to a lesser extent INH [13,14], but it
is less well-studied and understood for the injectable drugs.
To date, the primary genes associated with injectable drug
resistance in Mtb have been identified based on an understanding of
the mechanisms of action of the aminoglycosides (AMK, KAN) and
cyclic peptides (CAP) against Mtb. Both AMK and KAN bind to the
16SrRNAinthe 30S ribosomal subunit and inhibitproteinsynthesis
[15].The mechanism of action of CAP inMtb isnot wellunderstood,
but it appears to interfere with translation and inhibit phenylalanine
synthesis in mycobacterial ribosomes [16]. Mutations in Mtb,m o s t l y
non-synonymous, single nucleotide polymorphisms (SNPs), that
prevent the binding of the injectable drugs to their pathogen gene
targets or that change the mechanism of action of the drugs, have
been associated with drug resistance to AMK, KAN and CAP
[17,18]. The most well-studied gene mutations believed to confer
resistance to the injectable drugs lie in the rrs and tlyA genes. The rrs
gene encodes 16S rRNA [19] and tlyA encodes a 29-O-methyltrans-
ferase that modifies nucleotide C1409 in helix 44 of 16S rRNA and
nucleotide C1920 in helix 69 of 23S rRNA [20]. The mutations most
commonly reported to cause resistance to the injectable drugs
include: A1401G, C1402T, and G1484T in the rrs gene[9,10,18,21–
38]. More recently, the eis promoter, which has been demonstrated
to enhance the intracellular survival of a related bacterium—
Mycobacterium smegmatis—has also been considered for its utility as a
marker for resistance to KAN when mutated [39]. Other resistance-
associated mutations in these genes and other genes have been
proposed [32],buttheirutilityasaccuratepredictorsofresistancehas
yet to be demonstrated. Consequently, current molecular detection
tests for XDR-TB areconsidered inferior to thoseused for MDR-TB
due to insufficient knowledge about the keymutationsresponsiblefor
conferring resistance to AMK, KAN and CAP.
We therefore conducted a systematic review of all published
studies evaluating Mtb mutations associated with resistance to
AMK, KAN, CAP in order to characterize the diversity and
frequency of mutations as well as describe the strength of the
association between specific mutations and phenotypic resistance
in global populations. The objective of our study was to determine
the potential utility and reliability of these mutations as diagnostic
markers for detecting AMK, KAN and CAP resistance in Mtb.
Methods
Literature Search
A Medline search was conducted of all publications evaluating
mutations associated with resistance to AMK, KAN and CAP in
Mtb. The search was restricted to studies published from 1959
through September 10
th, 2011, including those studies available
online prior to publication. MEDLINE/PubMed key search terms
used were: (second-line OR kanamycin OR capreomycin OR
amikacin) AND (resistance OR resistant) AND tuberculosis AND
(mutation OR sequence OR gene).
Study Selection Criteria
Studies were included if they met the following predetermined
criteria: i) published in English; ii) presented original data; and iii)
assessed drug resistance mutations in clinical Mtb strains that were
resistant to AMK, KAN and/or CAP (in vitro studies were
excluded as laboratory generated mutations have been frequently
observed to be different from those found in clinical isolates [40]).
Studies were also excluded if they did not perform or describe
phenotypic drug susceptibility testing (DST), did not perform
sequencing as a method for determining drug resistance
mutations, or did not report specific mutation data. We included
studies that used both liquid and solid-based media for DST as
long as they reported clearly defined drug concentration cutoffs for
determining resistance. These criteria were intended to select the
broadest range of studies with the highest quality of specific data
for mutation analysis.
Data Extraction and Entry
From each publication, we extracted the following information:
authors, publication year, geographic origin of clinical strains,
reference strain(s) utilized to evaluate mutations, testing method for
phenotypic drug susceptibility and drug concentrations used for
defining resistance, methods used to detect genotypic mutations,
genes sequenced, and loci of genes sequenced. The following
mutation information was also recorded: specific gene mutation(s)
found, injectable drug utilized for selection, number of resistant and
susceptible isolates tested, and number of resistant and susceptible
isolates demonstrating mutation. Data were recorded and compiled
using Excel and Access software (Microsoft, Redmond, WA).
Data Collation and Cumulative Mutation Frequency
Calculations
Mutations associated with resistance to AMK, KAN, and CAP
were grouped by genes and stratified by the drug resistance
phenotype associated with the mutation. Data was examined for
evidence of individual as well as multiple mutations within a gene.
Each mutation reported in a resistant Mtb isolate was considered
independent of all others within and between studies (except where
otherwise noted for multiple mutations in the same gene), and
recorded as one instance of the mutation in the numerator of our
cumulative frequency calculations. Cumulative mutation frequen-
cy in resistant isolates was calculated as the number of resistant
isolates in which the mutation was found, divided by the total
number of phenotypically resistant isolates tested across studies.
Cumulative mutation frequency in susceptible isolates was calculated
as the number of susceptible isolates in which the mutation was
found, divided by the total number of susceptible isolates tested
across studies. As not all studies examined all mutations or all
genes associated with resistance, an isolate was only included in the
denominator of a cumulative frequency calculation for a particular
mutation if that mutation could have been detected in that isolate
(i.e. the study sequenced the appropriate section of the gene).
While all mutations identified in the review were evaluated, the
cumulative mutation frequency tables presented in this review
represent only the mutations that reached a frequency threshold as
described below. Isolates with rrs and gidB gene mutations were
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for any one of the injectable drugs tested, and when that frequency
was not higher among susceptible isolates than resistant isolates for
two or more injectable drugs. The isolates with tlyA gene, eis
promoter, and multiple rrs mutations were included in the tables if
the mutation frequency among resistant isolates was at least 1% for
any one of the injectable drugs tested. Mutations were excluded
from the tables when the frequencies of the mutation were equal in
resistant and susceptible strains (ie not likely to be associated with
resistance).
Quality Assessment and Consistency
Throughout this review mutation co-ordinates are referred to in
accordance with the numbering in the Mtb H37Rv complete
genome, accession number NC_000962, National Center for
Biotechnology Information [41]. Mutations identified in earlier
publications that did not use this co-ordinate system [21,22,25]
were updated to this numbering system. The H37Rv strain was
the assumed template for mutation analysis in all publications,
even when not explicitly stated within a given study, as is standard
practice [9,10,18,25,26,30].
In publications that did not examine the whole gene and did not
report the specific area of the gene sequenced, the reported SNPs
were substituted as the outer limits for the gene region under study
(e.g. if only rrs mutations A1401G and G1484T were reported
within a publication, the sequence from 1401–1484 was
considered to be the section of rrs analyzed for mutations). In
publications evaluating the MTBDRsl line probe assay (Hain Life
Sciences, Tu ¨bingen, Germany), in which resistance-associated
genes were sequenced, but sequence data was only provided for
regions hybridized to the line probes, only those SNPs tested via
hybridization strips were considered sequenced.
In one publication, mutation data was reported for ‘‘probable-
resistant’’ and ‘‘probable-susceptible’’ clinical isolates [33]. A
‘‘probable-susceptible’’ strain was defined as an Mtb strain isolated
prior to initiation of any treatment with a given drug, while a
‘‘probable-resistant’’ strain was defined as a strain isolated from
patients after at least six months of treatment with the given drug.
For the purposes of this review, we assumed the probable-resistant
and probable-susceptible isolates were resistant and susceptible
based on the DST methodology described in the manuscript.
Sensitivity and Specificity of Mutations
In order to comment on the potential predictive value of the
reported resistance-related mutations in a molecular diagnostic
test, we described a mutation as potentially ‘‘very sensitive’’ when
its cumulative frequency was 75% or more in the resistant strains
evaluated and ‘‘moderately sensitive’’ if it occurred in 50% to 74%
of the resistant strains reported. A resistance-related mutation was
defined as ‘‘very specific’’ if it was reported in 5% or less of
susceptible strains evaluated and ‘‘moderately specific’’ if it was
reported in 6% to 10% of the susceptible strains evaluated.
Results
Description of Included Studies
Figure 1 (Figure S1) illustrates the study selection and exclusion
process utilized for this review. Initial search parameters identified
135 studies published from November, 1959 through September,
2011. Twenty-two publications met all eligibility criteria and were
included in the review [6–27].
Of the 22 studies included, the earliest was published in 1998
and 17 (77%) were published in the last three years (Table 1).
Altogether, mutation data was provided for 1,585 unique clinical
isolates with various phenotypic resistance profiles to AMK, KAN,
and/or CAP. The reported geographic origins of these strains
were diverse, covering four continents and over 18 countries.
Mutations in the rrs, tlyA, eis promoter and gidB genes were
associated with Mtb resistance to AMK, KAN and/or CAP in the
examined literature. A total of 94 unique mutations were reported
relative to the reference H37Rv genome: rrs (37 unique mutations),
tlyA (30 unique mutations), eis (12 unique mutations) and gidB (15
unique mutations). Eighty-two of these mutations (87%) were
SNPs, six were deletions (one in rrs, two in tlyA and three in gidB),
and six were insertions (two in rrs and four in tlyA). As resistance
determination for the strains was crucial to our analysis, we
evaluated the DST methods and drug-concentration cutoffs used
in each study to define whether a strain was resistant or not.
Table 2 shows the method of DST and cutoff concentrations used
in each study as well as whether or not they conformed to
published standards. The drug concentrations used in all but three
studies [10,26,36] conformed to at least one national or
international published standard. As DST standards are somewhat
controversial and variable between countries, and the three studies
in question were all conducted by national reference laboratories,
we assumed their DST definition of resistance was correct for this
review. A PRISMA checklist is provided as befitting a systematic
review, to ensure integrity of the data (Table S1).
rrs Mutations Associated with Injectable Drug Resistance
Among the genes considered in the 22 papers reviewed, rrs was
the most extensively studied, but only eight papers (36%),
Figure 1. Study Selection Process and Reason for Exclusion of
Studies.
doi:10.1371/journal.pone.0033275.g001
Mutations and Resistance to Injectable Drugs in TB
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33275representing a total of 442 tested isolates (32% of the total),
included sequence data on the entire rrs gene. Figure 2 shows the
rrs studies as a heatmap of the number of isolates evaluated in each
study as well as the locations of the major mutations found. The
most commonly examined mutations were the A1401G mutation,
reported in all 21 papers with rrs mutations, and the G1484T
mutation, reported in 7/21 papers.
Table 3 shows the cumulative frequencies of the most
commonly reported mutations in the rrs gene. The A1401G
SNP was found in 387/493 (78%) of AMK-resistant (AMK
R)
strains and it was never observed in AMK-susceptible (AMK
S)
strains. It is notable that while 367/483 (76%) CAP-resistant
(CAP
R) isolates studied had the A1401G mutation, it was also
found in 45/678 (7%) of CAP-susceptible (CAP
S) strains tested
across 7 studies. However only 354/637 (56%) KAN-resistant
(KAN
R) isolates studied had the A1401G mutation, and it was
never reported in KAN-susceptible (KAN
S) strains. These studies
indicate that the A1401G mutation has potentially moderate
sensitivity for predicting resistance to all three drugs and the
potential to be a highly specific predictor for AMK and KAN
resistance, but less so for CAP.
Other notable rrs mutations included the A514C and C517T
SNPs, which were found in only 7%–10% and 4%–7% of resistant
strains, respectively. However, both mutations were also found in
2%–6% of isolates defined as susceptible to the injectable drugs.
Surprisingly, while the G1484T and C1402T mutations are
commonly cited as being strongly and commonly associated with
resistance, our review found that out of over 400 injectable drug
resistant strains evaluated, only 1% or less had these mutations.
The C1402T appears to occur as frequently in AMK
S and KAN
S
strains as it does in AMK
R and KAN
R strains suggesting it would
be a poor marker of resistance. The rrs mutation G1158T, while
studied in less than 300 injectable drug resistant strains, appears to
be at least as frequent in resistant strains as the 1484 and 1402 rrs
mutations, and has never been observed in the almost 150 strains
susceptible to AMK, KAN and/or CAP, suggesting it might be at
least as sensitive as 1484 and 1402 mutations and a more specific
predictor for injectable drug resistance.
Table 1. Details of Studies Included in Review and Source of Mycobactrium tuberculosis Isolates.
Clinical Isolates
PubMed ID
# of Clinical Isolates
Examined Origin of Isolates Clinical Institution(s) Providing Isolates Year of Collection
09574680 114 Japan Various hospitals Not stated
Japan Anti-TB Association
Research Institute of TB
Hiroshima University
09593173 17 Not stated PHRI TB Center, New York Not stated
12937004 49 Estonia Not stated 2001
15673735 18 Not stated CDC Not stated
16048924 16 Not stated CDC Not stated
19906990 58 Not stated CDC Not stated
19386845 106 Germany National Reference Laboratory Not stated
19470506 87 Uzbekistan Not stated 2003–2006
19634718 15 China Beijing TB and Lung Tumor Research Institute Not stated
19752274 145 Georgia Georgian National Reference Laboratory Not stated
19890396 11 South Africa Not stated 1994, 1995, 2005, 2006
20028780 26 Portugal Various hospitals and laboratories 2005
20032248 106 South Korea National Masan Tuberculosis Hospital Not stated
20185419 10 South Africa Groote Schuur Hospital 2006, 2009
20335420 52 France French Reference Center of Mycobacteria 2005–2009
20573868 62 Vietnam Pham Ngoc Thach Hospital 2005–2006
20713679 6 India Super Religare Laboratories Reference Center Not stated
20854453 133 Korea Korean Institute of Tuberculosis Not stated
USA Massachusettes State Laboratory Institute
Philippines Tropical Disease Foundation
Latvia State Agency of Tuberculosis and Lung Diseases
China Public Health Laboratory Centre
21300839 314 Not stated CDC Not stated
21427106 152 Various Countries Not stated Not stated
21562102 38 Taiwan Not stated 2008–2009
21732736 50 South Africa National Health Laboratory Services 2008–2009
CDC=Center for Disease Control and Prevention, Atlanta.
doi:10.1371/journal.pone.0033275.t001
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Upper Limit Drug Concentration used to determine
resistance (ml/ml)
PubMed ID DST Method AMK KAN CAP
DST Conforms to Published
Standard
19386845 MGIT 960 1.0 ND 2.5 Yes [73]
19470506 MGIT 960 1.0 ND 2.5 Yes [73]
20713679 MGIT 960 1.0 4.0 2.5 Yes [73]
21732736 MGIT 960 1.0 ND 2.5 Yes [73]
20028780 BACTEC 460 1.0 5.0 1.25 Yes [6]
20335420 Lowenstein-Jensen 20* 20 20* Yes* [74]
20573868 Lowenstein-Jensen ND 20 ND Yes [74]
20854453 Lowenstein-Jensen ND 30 40 Yes [75]
19634718 Lowenstein-Jensen 20* 20 ND Yes* [74]
19752274 Lowenstein-Jensen 40 30 40 Yes [73]
09593173 Lowenstein-Jensen ‘‘standard’’ ‘‘standard’’ ND Yes [75]
19890396 Lowenstein-Jensen ND 20 ND Yes [74]
12937004 Middlebrook 7H10 4.0 4.0 ND Yes [6,76]
20032248 Middlebrook 7H10 4.0 5.0 10 Yes [6,73,76]
15673735 Middlebrook 7H10 4.0 5.0 10 Yes [6,73,76]
16048924 Middlebrook 7H10 4.0 5.0 10 Yes [6,73,76]
19906990 Middlebrook 7H10 4.0 5.0 ND Yes [6,73,76]
21300839 Middlebrook 7H10 4.0 5.0 10 Yes [6,73,76]
21427106 Middlebrook 7H10 1.0 4.0 8.0 Yes [77]
20185419 Middlebrook 7H11 ND 6.0 ND Yes [73]
21562102 Middlebrook 7H11 6.0* 6.0 10 Yes* [73]
09574680 Ogawa Egg Medium ND ND 100 Yes [78]
*No publication found to validate DST concentration.
AMK=amikacin, KAN=kanamycin, CAP=capreomycin.
ND=not done.
doi:10.1371/journal.pone.0033275.t002
Figure 2. Heatmap of Reviewed Studies that Evaluated rrs Gene Mutations in Mycobacterium tuberculosis isolates. Graphic shows the
region of the rrs gene studied, the number of isolates tested in each study and the locations of the mutations found. The X-axis (nucleotide position)
has a 25 base pair resolution. The numbers of isolates varies from 314 (black) to 10 (lightest grey). Red indicates that a mutation has been found in
that 25 base pair region.
doi:10.1371/journal.pone.0033275.g002
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Sequence data for the tlyA gene was provided in only 8 of the 22
publications reviewed [18,24,28,31,33,35,37,38]. Mutations of the
tlyAgene have been mostwell-studied in CAP
R and CAP
S Mtb strains
(n=366 and 559, respectively), and have been evaluated in less than
260 KAN
R or AMK
R s t r a i n s( T a b l e4 ) .M u t a t i o n si nt h etlyA gene
associated with CAP
R were reported to be rare in the surveyed
literature (found in ,1–3% of resistant strains). However, when
reported, they were not found in any CAP
S strains, making them
potentially highly specific markers of CAP resistance. Of the 559 total
CAP
S isolates reported in 7 studies [18,24,28,31,33,35,37,38], none
had any mutations within the tlyA gene. A GT insertion at position
755 of the tlyA gene was the only mutation that was found in more
than 1% of CAP
R strains (3% of strains had this mutation).
eis Promoter Mutations Associated with Injectable Drug
Resistance
Mutations within the eis promoter region of Mtb have only been
evaluated in a few hundred injectable drug resistant strains
(Table 5) and were reported to be largely associated with KAN
resistance [37,39]. The most frequently reported eis promoter SNP
(G-10A) was found in 66/296 (22%) of the KAN
R strains
studied—second only to the frequency of the rrs A1401G mutation
in injectable drug resistant strains—and was found in only 2/266
(1%) of KAN
S strains. The C-14T SNP was reported in modest
frequency in both KAN
R and AMK
R strains (11% and 9%
respectively) and was not found in susceptible strains. eis promoter
mutations were also reported in up to (9%) CAP
R strains. Aside
from the C-12T SNP, however, which was reported in 5/93 (5%)
of CAP
R strains and 1/93 (,1%) of CAP
S strains, these mutations
appear to be non-specific markers of resistance, occurring in up to
29% of CAP
S strains.
gidB Mutations Associated with Injectable Drug
Resistance
The reported gidB mutations associated with injectable drug
resistance have only been evaluated in 20 strains resistant to
AMK, KAN and/or CAP (Table 6), producing what are likely
unreliable cumulative frequencies. The G102 deletion appeared
with a high frequency among resistant isolates (17–20%), and was
only found in one susceptible isolate examined. The T230C,
Table 3. Cumulative Frequencies of Selected Mutations within the rrs Gene among Mycobacterium tuberculosis Isolates Resistant
or Susceptible to Amikacin (AMK), Kanamycin (KAN) and/or Capreomycin (CAP).
Mutation
Drug
Tested #R Examined #S Examined
#R with
Mutation
#S with
Mutation
Frequency of
Mutation among R
Frequency of
Mutation among S
A1401G AMK 493 703 387 0 0.78 0.00
KAN 637 643 354 0 0.56 0.00
CAP 483 678 367 45 0.76 0.07
A514C AMK 200 263 20 15 0.10 0.06
KAN 269 236 23 12 0.09 0.05
CAP 195 273 14 14 0.07 0.05
C517T AMK 200 263 14 10 0.07 0.04
KAN 269 236 20 5 0.07 0.02
CAP 195 273 8 14 0.04 0.05
A513C AMK 196 260 1 1 0.01 0.00
KAN 259 239 9 4 0.03 0.02
CAP 190 271 1 1 0.01 0.00
G1484T AMK 491 666 5 1 0.01 0.00
KAN 616 654 9 0 0.01 0.00
CAP 483 678 2 0 0.00 0.00
C1402T AMK 443 624 3 6 0.01 0.01
KAN 525 543 5 4 0.01 0.01
CAP 434 637 7 0 0.02 0.00
G1158T AMK 206 133 2 0 0.01 0.00
KAN 273 116 2 0 0.01 0.00
CAP 201 149 2 0 0.01 0.00
A907C AMK 200 263 2 1 0.01 0.00
KAN 259 236 2 1 0.01 0.00
CAP 190 271 1 1 0.01 0.00
C1402 AMK 443 624 0 1 0.00 0.00
KAN 525 543 3 0 0.01 0.00
CAP 434 637 1 0 0.00 0.00
R=Resistant isolates.
S=Susceptible isolates.
doi:10.1371/journal.pone.0033275.t003
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drug resistant strain and did not appear to occur in strains
susceptible to AMK, KAN and/or CAP.
Double Mutations in the rrs Gene Associated with
Injectable Drug Resistance
Only a small number of the surveyed publications described
specific mutations at more than one site in any of the genes
evaluated, limiting our ability to calculate cumulative frequencies
of such ‘‘multiple mutations’’ in injectable drug resistant strains.
We therefore report here only specific double mutations within the
most commonly described gene (rrs). The most common double
mutations reported always included the A1401G mutation
(Table 7). While the cumulative frequency of double mutations
did not exceed 5% in injectable drug resistant strains, an A1401G
mutation together with A514C, A513C or A1338C SNP occurred
only in resistant strains and was not reported to occur in any
strains susceptible to AMK, KAN and/or CAP, whereas the
A1401G mutation alone was found to occur in up to 7% of CAP
S
strains (Table 3). This suggests that multiple rrs mutations might be
a highly specific predictor of injectable drug resistance when
detected (i.e., never observed in susceptible strains).
Discussion
It is clear from the literature reviewed that Mtb mutations
associated with injectable drug resistance are understudied
compared to the mutations associated with resistance to first-line
drugs [42]. Only the 1401 and 1484 positions of the rrs gene have
been evaluated to any extent in injectable drug resistant isolates
(n.600), while the remainder of the rrs and other resistance-
associated genes (tlyA and the eis promoter) have each been
evaluated in less than 400 drug resistant Mtb isolates. Only 20
injectable drug resistant isolates have been examined for gidB
mutations. This review uncovered evidence to suggest that certain
mutations outside the commonly-observed A1401G SNP, alone or
in conjunction with rrs mutations, could help to detect some of the
25%–40% of AMK, KAN, and CAP resistant Mtb strains that do
not appear to have an rrs mutation.
Future studies of Mtb resistant to AMK, KAN and CAP should
always include a comprehensive sequence analysis of at least the
entire four genes examined here, if not the entire Mtb genome.
Additionally, a suitable number of injectable drug susceptible
strains should be included in each study to build data on the
potential specificity of each mutation. As the sensitivity of any
mutation-based molecular diagnostic will be determined by both
the strength of the association between mutation and phenotypic
resistance and the frequency of the specific resistance-related
mutation in the population, it is also crucial to establish both
regional and global frequencies of these mutations to predict
where and how to develop the most effective molecular
diagnostics.
Mutations as Markers of Phenotypic Resistance to the
Injectable Drugs
Certain rrs, tlyA, eis promoter and gidB gene mutations with the
potential to be both sensitive and specific predictors of phenotypic
drug resistance were found frequently in drug-resistant strains and
infrequently, or never, in drug-susceptible strains. Compared to
INH-resistant Mtb strains (,85% of which have katG and/or inhA
promoter mutations) [43] and RIF resistant strains (,97% of
which have rpoB mutations) [44], phenotypic resistance to AMK,
Table 4. Cumulative Frequencies of Selected Mutations within the tlyA Gene among Mycobacterium tuberculosis Isolates Resistant
or Susceptible to Amikacin (AMK), Kanamycin (KAN) and/or Capreomycin (CAP).
Mutation Drug Tested #R Examined #S Examined
#R with
Mutation
#S with
Mutation
Frequency of
Mutation among R
Frequency of
Mutation among S
insGT755 AMK 257 221 2 9 0.01 0.04
KAN 223 118 9 2 0.04 0.02
CAP 366 559 11 0 0.03 0.00
G223T AMK 257 184 2 0 0.01 0.00
KAN 223 118 2 0 0.01 0.00
CAP 366 559 2 0 0.01 0.00
insGC202 AMK 257 221 0 0 0.00 0.00
KAN 223 118 0 0 0.00 0.00
CAP 366 559 2 0 0.01 0.00
Gly196Glu* AMK 257 221 0 0 0.00 0.00
KAN 223 118 0 0 0.00 0.00
CAP 366 559 2 0 0.01 0.00
T220C AMK 257 221 0 0 0.00 0.00
KAN 223 118 0 0 0.00 0.00
CAP 366 559 2 0 0.01 0.00
T708G AMK 257 221 0 3 0.00 0.01
KAN 223 118 0 3 0.00 0.03
CAP 366 559 3 0 0.01 0.00
*Represents an amino acid change, as specific nucleotide changes were not provided for this mutation.
R=Resistant isolates.
S=Susceptible isolates.
doi:10.1371/journal.pone.0033275.t004
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Resistant or Susceptible to Amikacin (AMK), Kanamycin (KAN) and/or Capreomycin (CAP).
Mutation Drug Tested #R Examined #S Examined
#R with
Mutation
#S with
Mutation
Frequency of
Mutation among R
Frequency of
Mutation among S
G-10A AMK 118 72 12 27 0.10 0.38
KAN 296 266 66 2 0.22 0.01
CAP 93 97 8 28 0.09 0.29
C-14T AMK 118 72 11 0 0.09 0.00
KAN 296 266 32 0 0.11 0.00
CAP 94 97 5 6 0.05 0.06
C-12T AMK 118 72 7 0 0.06 0.00
KAN 296 266 9 6 0.03 0.02
CAP 93 97 5 1 0.05 0.01
G-37T AMK 118 72 2 0 0.02 0.00
KAN 296 266 15 0 0.05 0.00
CAP 93 97 0 2 0.00 0.02
G-10C AMK 118 72 1 0 0.01 0.00
KAN 296 266 1 0 0.00 0.00
CAP 93 97 1 0 0.01 0.00
G-6T AMK 118 72 1 0 0.01 0.00
KAN 296 266 1 0 0.00 0.00
CAP 93 97 1 0 0.01 0.00
C-15G AMK 118 72 1 0 0.01 0.00
KAN 296 266 1 0 0.00 0.00
CAP 93 97 0 1 0.00 0.01
R=Resistant isolates.
S=Susceptible isolates.
doi:10.1371/journal.pone.0033275.t005
Table 6. Cumulative Frequencies of Selected Mutations within the gidB Gene among Mycobacterium tuberculosis Isolates Resistant
or Susceptible to Amikacin (AMK), Kanamycin (KAN) and/or Capreomycin (CAP).
Mutation Drug Tested #R Examined #S Examined
#R with
Mutation
#S with
Mutation
Frequency of
Mutation among R
Frequency of
Mutation among S
DG102* AMK 17 89 3 1 0.18 0.01
KAN 20 86 3 1 0.15 0.01
CAP 18 88 3 1 0.17 0.01
T230C AMK 17 89 1 0 0.06 0.00
KAN 20 86 1 0 0.05 0.00
CAP 18 88 1 0 0.06 0.00
C286T AMK 17 89 1 0 0.06 0.00
KAN 20 86 1 0 0.05 0.00
CAP 18 88 1 0 0.06 0.00
T104G AMK 17 89 1 0 0.06 0.00
KAN 20 86 1 0 0.05 0.00
CAP 18 88 1 0 0.06 0.00
A254G AMK 17 89 1 1 0.06 0.01
KAN 20 86 1 1 0.05 0.01
CAP 18 88 1 1 0.06 0.01
All mutations in this table represent mutations found via sequence analysis in just one study [32].
*D Represents nucleotide deletion. SNPs were grouped for brevity.
R=Resistant isolates.
S=Susceptible isolates.
doi:10.1371/journal.pone.0033275.t006
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each with lower cumulative frequencies.
The rrs A1401G SNP was reported in about 75% of CAP
R and
AMK
R strains, and in less than 60% of KAN
R strains, and it was
only found in 7% of strains susceptible to CAP, suggesting this
mutation would be a very sensitive and specific marker for
phenotypic resistance to AMK, a very sensitive but moderately
specific marker for phenotypic resistance to CAP, and a
moderately sensitive but very specific marker for resistance to
KAN.
It appears that a single mutation, or even a set of mutations in a
single gene, does not adequately predict phenotypic resistance to
AMK, KAN and CAP. It is likely that a combination of different
gene mutations for each injectable drug will be needed to best
predict phenotypic resistance, as has been reported for the
molecular detection of INH resistance [45].
Based on the published mutation frequencies we report here,
KAN
R strains might be predicted with highest sensitivity and
specificity using a combination of rrs mutations (e.g. A1401G and
C517T) and eis promoter mutations (e.g. G-10A and C-14). Since
eis promoter mutations reportedly occur almost exclusively in
KAN
R strains with no 1401 rrs mutation [37,39] it is likely that this
approach will be considerably more sensitive than using the rrs
1401 mutation alone. CAP
R strains, on the other hand, appear to
be best predicted by mutations in rrs gene (i.e., A1401G, C1402T,
G1158T) possibly together with mutations such as C-12T in the eis
promoter, which was reported in 5% of CAP
R strains and only 1%
of CAP
S strains. Another useful marker might be the insertion at
position 755 of the tlyA gene; however, future studies will be
needed to confirm the frequency of this, and other, mutations in
CAP
R strains worldwide. For AMK
R strains, a combination of the
A1401G rrs SNP together with the eis promoter mutations C-14T
or C-12T (reported in 9% and 6% of AMK
R strains) could
increase sensitivity of resistance detection without decreasing
specificity. There was not sufficient data to evaluate the potential
role of double rrs mutations, but given that they were never
reported in injectable drug susceptible Mtb strains, these mutations
could significantly increase the positive predictive value of rapid
diagnostics when found.
It is important to note that resistance to streptomycin (SM), an
aminoglycoside with a similar mechanism to AMK and KAN [46],
was not evaluated in this review as it is not as well-studied as the
XDR-TB defining drugs. It is possible this exclusion may have
confounded some of our findings regarding mutations in gidB and
rrs. As SM is often administered together with AMK, KAN or
CAP, and SM resistance has been associated with mutations in
gidB [47] and the 500 region of rrs [48], that are not thought to
cross-react with AMK, KAN or CAP resistance; it is possible that
the associations we observed in these gene regions are a reflection
of underlying, but unevaluated SM resistance rather than true
associations with AMK, KAN and CAP resistance. Further study
of these mutations in the absence of SM resistance could shed
important light on the value of these mutations.
Improving the Detection of AMK, KAN and/or CAP
Resistance with Existing Molecular Diagnostics
In considering the implications of our findings, we focus upon
three commercially available molecular diagnostics employed to
detect resistance-related mutations in Mtb clinical isolates [49]:
hybridization-based tests, pyrosequencing, and molecular beacon
testing. Hybridization tests, such as the MTBDRplus and
MTBDRsl line probe assays (LPAs) (Hain Life Sciences, Tu ¨bin-
gen, Germany), are based on the hybridization of specific
mutations in clinical strains to a probe that is complimentary to
the mutated DNA. The MTBDRplus/sl assays are the only
commercially available rapid molecular diagnostics currently in
broad use for the detection of both MDR-TB and XDR-TB. They
have shown great promise in field studies for the detection of
MDR-TB [8,50–60], but variable sensitivity (40%–100% depend-
ing on the number of strains examined) for detection of injectable
drug resistance [9,10,29,36,61]. As the MTBDRsl LPA detects
only mutations in the 1401, 1402 and 1484 positions of the rrs
gene, the varying sensitivity of the test is in agreement with the
apparent cumulative frequency of these mutations in the published
literature. It would also seem from the very low cumulative
frequencies of the rrs 1402 and 1484 mutations reported, that their
inclusion in the MTBDRsl LPA as the only mutations outside of rrs
1401, might be limiting the potential sensitivity of this test for the
Table 7. Cumulative Frequencies of Multiple Mutations within the rrs Gene among Mycobacterium tuberculosis Isolates Resistant or
Susceptible to Amikacin (AMK), Kanamycin (KAN) and/or Capreomycin (CAP).
Mutation 1 Mutation 2
Drug
Tested #R Examined #S Examined
#R with
Mutation
#S with
Mutation
Frequency of
Mutation among R
Frequency of
Mutation among S
A1401G A514C AMK 200 263 10 0 0.05 0.00
KAN 269 236 10 0 0.04 0.00
CAP 195 273 10 0 0.05 0.00
A1401G A1338C AMK 293 473 5 0 0.02 0.00
KAN 404 405 5 0 0.01 0.00
CAP 288 482 5 0 0.02 0.00
A1401G A513C AMK 196 260 1 0 0.01 0.00
KAN 259 239 8 0 0.03 0.00
CAP 172 259 1 0 0.01 0.00
G1484T C1402A AMK 443 624 0 1 0.00 0.00
KAN 525 543 3 0 0.01 0.00
CAP 434 637 1 0 0.00 0.00
R=Resistant isolates.
S=Susceptible isolates.
doi:10.1371/journal.pone.0033275.t007
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probes could potentially increase MTBDRsl sensitivity by as much
as 10% without significantly decreasing specificity. In a recent
evaluation study of the MTBDRsl test, the inclusion of mutations
from a second gene, the eis promoter, increased field sensitivity for
KAN
R detection by about 30% [36].
Pyrosequencing is a rapid sequencing method used to detect
genetic mutations based on ‘‘sequencing by synthesis’’. It has been
established as a valid rapid method for detecting resistance-
associated SNPs in MDR-TB strains [62–66], but only one small
study reported on its use for XDR-TB detection [59]. A large,
multinational field study of suspected M/XDR-TB patients in
India, Moldova and South Africa [67] is currently evaluating the
effectiveness of pyrosequencing for detecting resistance to AMK,
KAN and CAP based on detection of mutations in the rrs gene
between base pair 1397 through 1406. Increasing the number of
mutations and genes currently being detected by pyrosequencing in
this study could significantly improve the next iteration of the assay.
Beacon-type sequencing, or SNP genotyping, has shown
excellent utility in the field [68–71] and is the basis of the
GeneXpert assay that was recently endorsed by WHO for
detecting RIF resistance in Mtb [72]. Unfortunately, this
technology is still being developed for XDR-TB detection, and
there is a risk that detection of second-line drug resistance may fall
behind unless the study of the appropriate mutations is
accelerated. Beacon technology is based on detection of short
stretches of genes that are different from the wild type genome,
rather than detecting point mutations like an LPA. Nonetheless, it
could similarly be developed to detect a variety of mutations in
short regions of the rrs, eis promoter, tlyA, and gidB genes if the
limitations in beacon development for these regions can be
overcome.
Limitations
The cumulative frequencies we calculated were based on several
assumptions, but the two we describe here are the most important.
First, we assumed that all the mutations reported were
independent of each other. If some isolates were misclassified as
independent when they were in fact not, this could have caused an
overestimation in our cumulative frequencies of that specific
mutation. Every effort was made to ensure that the isolates and the
mutations presented in one study were not also reported in
another study. All manuscripts were carefully examined to identify
isolates that were used in more than one study (e.g., same isolate
origin, same authors or organization, etc.) and to the best of our
knowledge, all isolates reported here are unique. A second
potential source of misclassification error was in our use of the
DST results as reported. For example, if an isolate was
misclassified as resistant based on faulty DST data, when it was
in fact susceptible, and it did not have the expected mutation, then
we would have underestimated the cumulative frequency of that
mutation among resistant isolates. To minimize the chances of
such misclassification, we excluded manuscripts without explicit
descriptions of their DST methods and clear definitions of what
constituted a resistant or susceptible isolate using accepted DST
drug concentrations and methodologies.
Conclusion
It is clear that the rrs 1401 mutation alone was not found with
sufficient frequency to detect more than 70–80% of global Mtb
strains resistant to AMK and CAP, and 60% of strains resistant to
KAN. While this is likely sufficient for a rapid screening test, future
molecular diagnostics will need to include more mutations in more
genes in order to accurately and sensitively detect resistance and
cross-resistance to AMK, KAN and CAP for clinical decision-
making purposes.
Other SNPs in the rrs, eis promoter, tlyA and gidB appear to be
very promising markers for improving both sensitivity and
specificity of detection of AMK, KAN and CAP resistance and
cross-resistance, but it is likely that each drug will need to be
considered independently (with independent mutation profiles) to
maximize the diagnostic and clinical utility of future molecular
diagnostics for these drugs.
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